Contribute Try STAT+ Today

Good morning, everyone, and nice to see you again after an extended holiday break on this side of the pond. We hope the respite was refreshing and invigorating, because the usual routine of Zoom meetings, Skype calls, and deadlines has predictably returned. But what can you do? Despite the gloom and doom, the world keeps spinning. So time to grab a cup of stimulation — coconut is our choice today — and get cracking. On that note, here are a few items of interest to jumpstart your day. We hope all goes well, and do keep in touch. …

Moderna (MRNA) reported that its Covid-19 vaccine continued to deliver strong results, showing 94% efficacy in the main analysis of its key study and, as a result, the company will immediately seek regulatory clearances in the U.S. and Europe, STAT writes. The milestone suggests there could be two vaccines before the end of 2020. Pfizer (PFE) and BioNTech (BNTX) released positive results for a similar vaccine on Nov. 18, and requested an emergency use authorization from the Food and Drug Administration two days later.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.